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AJOG at a Glance 
 
Why was the study conducted? 
Vaginal cerclage is recommended in women with evidence of cervical insufficiency, for 
example a history of multiple recurrent mid trimester losses or early preterm birth. When 
vaginal cerclage fails, transabdominal cerclage has been advocated, with observational 
studies suggesting higher rates of success. We searched PubMed for originala ticles 
published in English prior to September 2018 with the search terms “preterm birth OR 
cerclage OR transabdominal cerclage OR high vaginal cerclage”. There were no 
randomised studies that compared abdominal versus repeat vaginal cerclage.  
 
What are the key findings?  
This randomised controlled trial provides the first direct comparison of abdominal and 
high vaginal cerclage with low vaginal cerclage. Abdominal cerclage was demonstrated to 
be superior to low vaginal cerclage in women with prior failed cerclage in preventing 
early preterm birth (less than 32 weeks) and fetal loss. High vaginal cerclage was no better 
than low vaginal cerclage in preventing early birth.  
 
What does this study add to what is already known?  
Women with a prior failed vaginal cerclage (pregnancy delivered before 28 weeks of 
gestation) should be offered an abdominal cerclage, either before or in early pregnancy.  
 
 4 
ABSTRACT  63 
Background 64 
Vaginal cerclage (a suture around the cervix) is comm nly placed in women with recurrent pregnancy loss. 65 
These women may experience late miscarriage or extreme preterm delivery, despite being managed with 66 
cerclage. Transabdominal cerclage has been advocated following failed cerclage, although its efficacy is 67 
unproven by randomised controlled trial.  68 
 69 
Objective 70 
The objective of this study was to compare transabdominal cerclage or high vaginal cerclage to low vagin l 71 
cerclage in women with a history of failed cerclage. Our primary outcome was delivery before 32 completed 72 
weeks of pregnancy.  73 
 74 
Study Design 75 
This was a multicentre randomised controlled trial. Women were randomly assigned (1:1:1) to receive  76 
transabdominal cerclage, high vaginal cerclage or low vaginal cerclage, either prior to conception or before 14 77 
weeks’ gestation. 78 
Results 79 
111/139 women recruited who conceived were analysed: 39 to transabdominal cerclage, 39 to high vaginal 80 
cerclage and 33 to low vaginal cerclage. Rates of preterm birth <32 weeks were significantly lower in women 81 
who received transabdominal cerclage compared to low vaginal cerclage [8% (3/39) v 38% (15/39), RR 0.23 82 
(95% CI 0.07 to 0.76), p=0.0078]. Number needed to treat to prevent one preterm birth was 3.9 (95% CI 2.2 to 83 
13.3). There was no difference in preterm birth rates between high and low vaginal cerclage [38% (15/39) vs 84 
33% (11/33), RR 1.15 (95% CI 0.62 to 2.16), p=0.81].  85 
No neonatal deaths occurred. In an exploratory analysis, women with transabdominal cerclage had fewer fetal86 
losses compared to low vaginal cerclage [3% (1/39) vs 21% (7/33), RR 0.12 (95% CI 0.016 to 0.93), p=0.02]. 87 
Number needed to treat to prevent one fetal loss was 5.3 (95% CI 2.9 to 26).  88 
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Conclusions 89 
Transabdominal cerclage is the treatment of choice f r women with failed vaginal cerclage. It is superior to low 90 
vaginal cerclage in reducing risk of early preterm birth and fetal loss in women with previous failed vaginal 91 
cerclage. High vaginal cerclage does not confer this benefit. Numbers needed to treat are sufficiently low to 92 
justify transabdominal surgery and caesarean delivery required in this select cohort.    93 
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BACKGROUND   94 
Recurrent late miscarriage and early spontaneous preterm birth is often treated with vaginal cerclage (a suture 95 
placed around the cervix). This is known to have a significant benefit in a small number of cases probably 96 
representing those with genuine cervical incompetence, or who have traumatic cervical damage, such as th t 97 
caused by surgery(1). When evaluated by randomised controlled trial (RCT), vaginal cerclage (VC) has limited 98 
value, compared to conservative management (numbers ne ded to treat were 25)(2). Even without cerclage, most 99 
women will have a successful subsequent pregnancy. The challenge is to identify those women whose 100 
pregnancy losses are genuinely due to cervical weakness; women who experience multiple late miscarriages or 101 
early spontaneous preterm births are more likely to fall into that category.  102 
In women for whom vaginal cerclage fails, abdominal cerclage (TAC, inserted laparoscopically or via 103 
laparotomy) has been advocated but requires more extensive surgery than vaginal cerclage, and caesarean 104 
delivery. A number of observational series(3–6) have suggested that abdominal cerclage is highly successful, 105 
however abdominal cerclage has never been evaluated in an RCT.  106 
We hypothesised that abdominal cerclage (TAC) would result in lower rates of late miscarriage and early 107 
preterm delivery compared to low vaginal cerclage (LVC) by maintaining structural and biochemical integrity 108 
of the cervix because it is placed higher in the cervix, ideally at the level of the internal os. This may prevent the 109 
infective/inflammatory cascade associated with cervi al shortening(7), which may be due either to stretch of the 110 
fetal membranes as the internal os opens(8), or loss of the cervical barrier to ascending infection(7). A VC can 111 
also be placed higher in the cervix, by mobilising the bladder (HVC). It is unknown whether this also results in 112 
lower rates of late miscarriage or PTB when compared to LVC.  113 
 114 
METHODS 115 
Study design and participants 116 
The MAVRIC trial was a multicentre RCT funded by the J P Moulton Charitable Foundation and supported by 117 
the NIHR Clinical Research Network (CRN). NHS Research Ethical Committee approval was obtained (REC 118 
07/H1102/113) and the trial was registered on the Int rnational Standard Randomised Controlled Trial Registry 119 
(ISRCTN33404560).  120 
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 121 
Women were eligible for trial inclusion if they had  history of spontaneous late miscarriage or preterm birth 122 
between 14 and 28 completed weeks of pregnancy with low vaginal cerclage (LVC) in situ, but excluding 123 
rescue cerclage procedures, i.e. cerclage inserted with exposed membranes. Women were eligible for 124 
randomisation pre-conceptually or at less than 14 weeks’ gestation. Only data from the first pregnancy 125 
following randomisation was analysed (figure 1). 126 
Participants were referred from hospitals across the United Kingdom and recruited at 9 sites (London (4 sites), 127 
Kirkcaldy, Sunderland, Newcastle, Bradford and Edinburgh) between January 2008 and September 2014. All 128 
participants gave written informed consent and were over the age of 16. 129 
 130 
Procedures 131 
Women with a previous failed cerclage were randomised to one of the following: 132 
1. TAC: Transabdominal cerclage 133 
2. HVC: High vaginal cerclage  134 
3. LVC: Low vaginal cerclage  135 
Techniques used were left to the local clinician’s discretion. Details of surgical and anaesthetic technique were 136 
collected (table 6). All procedures were carried out by a consultant level surgeon (table 7). Vaginal cerclage was 137 
inserted prior to 16 weeks’ under regional anaesthetic and removed at 37 weeks' gestation, or earlier if preterm 138 
labour ensued. HVC involved mobilisation of the bladder from the anterior cervix allowing the suture to be 139 
placed higher, and usually required regional anaesthetic for removal.  TAC was placed pre-conceptually or 140 
before 14 weeks' gestation as an open procedure under either regional or general anaesthetic, requiring inpatient 141 
stay of up to 3 days. Women with TAC were scheduled for delivery by elective caesarean section at 38 to 39 142 
weeks, with retention of the TAC for future pregnancies.  143 
 144 
Randomisation and masking 145 
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Women enrolled in MAVRIC were randomly assigned to TAC, HVC or LVC (1:1:1) using a computer-146 
generated randomisation procedure incorporated in ainternet-based secure trial database 147 
(www.medscinet.net/MAVRIC). Minimisation was used to balance two prognostic variables: pregnancy at time 148 
of randomisation and gestational age of previous late miscarriage or preterm delivery (Table 1).  Due to the 149 
nature of the interventions, treatment allocation was known to both participants and health care professionals. 150 
Written informed consent was obtained from all participants and baseline demographic characteristics, r sk 151 
factors and obstetric and gynaecologic history were ent red into the study specific database.  152 
Cerclage insertion was performed electively between 10 to 16 weeks’ (14 weeks for TAC) or pre-conception if 153 
assigned to TAC or HVC, according to clinician and patient preference. All LVCs were carried out at the154 
women’s local maternity unit. As HVCs and TACs are more specialist procedures, these were carried out in one 155 
of the designated centres, to ensure a suitably experienced surgeon completed the procedure. Following cerclage 156 
insertion, women were monitored and managed according to local clinicians’ practice. All care was in le with 157 
contemporaneous evidence-based guidelines.  158 
 159 
Outcomes 160 
Our primary outcome on which the trial was powered was delivery before 32 completed weeks of pregnancy. 161 
Pre-defined secondary outcomes included neonatal deth, serious operative complication rates and 162 
complications of pre- and post-conception cerclage (HVC and TAC).  163 
Pregnancy outcomes were obtained from case note revi w, by trained research midwives. Women were 164 
considered to have had a spontaneous preterm birth (sPTB) if they had spontaneous onset of labour, or 165 
experienced preterm rupture of membranes and deliver d prematurely, regardless of mode of delivery. There 166 
were no changes to pre-specified outcomes during recruitment. All pre-specified analyses were undertaken.  167 
As there were no neonatal deaths, we performed an additional analysis by comparing the overall fetal loss rate 168 
by trial arm (composite of late miscarriage and stillbirth).  169 
 170 
Sample size calculation 171 
 9 
Sample size estimation was informed by data from an observational study by Davis et al. (4), the best available 172 
evidence at the time. Our primary outcome was rate of delivery before 32 complete weeks of gestation. 173 
Assuming a baseline event rate of 38% with LVC and 10% with TAC (4), a total of 43 women in each of the 174 
three groups (TAC, HVC and LVC) was required for 80% power, at the 5% significance level (2-tailed), to 175 
show a significant difference between LVC and the other two groups (effect of 28% absolute risk reduction).  176 
Given this was a feasibility trial we made no adjustments for multiple testing. 177 
  178 
Statistical analysis 179 
Statistical analyses were undertaken in Stata version 14·2 (StataCorp 15.1, College Station, Texas). Analysis 180 
was by modified intention-to-treat, with planned comparison of treatment effects for binary endpoints using risk 181 
ratios and significance tests for both primary and secondary endpoints. The modification was to take into182 
account patients who did not conceive post-randomisation. A vaginal cerclage is unlikely to be considered in a 183 
non-pregnant patient and therefore these women wereremoved to ensure the analysis remained clinically va id. 184 
We also performed a per protocol analysis, although this was not predefined. 185 
Role of the funding source 186 
The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing 187 




This was a multicentre RCT, with patients as the unit of randomisation. The full study protocol can be found on 192 
the King’s College London website 193 
(https://www.kcl.ac.uk/lsm/research/divisions/wh/clinical/open/mavric.aspx). 194 
139 participants were recruited and randomly allocated a treatment. The first patient was recruited in Ja uary 195 
2008. Recruitment ended in September 2014, when the planned recruitment target (n=129) had been exceeded. 196 
Seventy-nine women were not pregnant at the time of randomisation, which was a higher number than 197 
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anticipated. At this time 104 women had conceived. Four years later, only 7 additional women had conceived 198 
and delivered (1 in 2014, 4 in 2015 and 2 in 2017). Despite extensive efforts, we were unable to trace the 199 
outcomes of two participants who were known to have moved abroad.   200 
The data monitoring committee was consulted in September 2018; there had been no further conceptions during 201 
the preceding 12 months, and therefore the decision was made to proceed with analysis on 111 women. Only202 
data from the next pregnancy following randomisation was analysed (Figure 1).  203 
Of the 111 participants who had conceived and with known outcome, 39 were randomised to TAC, 39 to HVC 204 
and 33 to LVC. All first trimester miscarriages (less than 13 weeks’) post randomisation were excluded from the 205 
analysis (3 excluded: 1 in TAC, 1 in HVC and 1 in LVC group). Almost half (49%, 19/39) of TACs were placed 206 
pre-conception; all of the HVC and LVC were placed prior to 16 weeks’ gestation. 207 
Baseline demographic characteristics are shown in Table 2. The median gestation of failed cerclage was 22 208 
weeks (IQR 20 to 24). Our inclusion criteria defined cerclage failure as preterm delivery before 28 weeks, 209 
however 69% (96/139) of women had a failed cerclage that resulted in late miscarriage (<24 weeks). 97%, 95% 210 
and 91% of each randomised group had 2 or more late second trimester losses (95% of the whole group, 211 
105/111). Most others had cervical shortening detect d during screening for a prior preterm loss.  212 
Patients were managed as per local clinical practices: 17% (6/36) of women allocated to TAC were also 213 
prescribed progesterone, 28% (10/36) with HVC and 48% (14/29) with LVC. All women had a history of 214 
recurrent early delivery: the median number of latemiscarriages was 2 (IQR 1 to 5) and preterm births were 1 215 
(IQR 0 to 5).  216 
 217 
Outcomes 218 
There was a statistically significant reduction in preterm birth less than 32 completed weeks’ gestation l age 219 
(the primary outcome) in women allocated to TAC compared to LVC  [8% (3/39) v 38% (15/39), RR 023 220 
(95% CI 007 to 076) p=00078]. There were no iatrogenic preterm deliveries among these women. Number 221 
needed to treat (NNT) to prevent one sPTB was 3.9 (95% CI 22 to 133). There was no difference in rates of 222 
sPTB between high and low VC [38% (15/39) vs 33% (11/33), RR 115 (95% CI 062 to 216), p=081]. 223 
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TAC also demonstrated benefit when compared to HVC [8% (3/39) v 38% (15/39), RR 02 (95% CI 0063 to 224 
064), p=00024]. NNT was 32 (95% CI 20 to 74) (see Figure 2).  225 
No neonatal deaths occurred. Women with a TAC had fewer fetal losses (late miscarriage or stillbirth), 226 
compared to LVC [3% (1/39) vs 21% (7/33), RR 012 (95% CI 0016 to 093), p=002]. NNT to prevent 227 
one fetal loss was 53 (95% CI 29 to 26).  228 
Serious adverse events (pre-defined as per protocol) were reported in four cases (2 x cervical tears, 1 x ITU 229 
admission with sepsis and 1 case of cardiomyopathy), all of which occurred in women with high (n=3) or l w 230 
(n=1) vaginal cerclage. 6 women received a subsequent rescue cerclage (4 who were allocated HVC, 2 who231 
were allocated LVC). The indication for rescue cerclage was painless dilatation identified during routine 232 
preterm birth surveillance assessments (data only available for 3/6 women). Table 6 gives surgical and 233 
anaesthetic details for each procedure divided by outcome; no specific trends are apparent, and techniques are 234 
equally spread across the outcome groups.  235 
72% (28/39) of women with a TAC in situ delivered at term, compared to fewer than half of w men with HVC 236 
(46%, 18/39) or LVC (48%, 16/33) (Table 4).  237 
Eight women did not receive treatment as per allocati n (see Table 5), as a result of patient choice following 238 
randomisation or treatment allocation being judged inappropriate, for example, the cervix was found to be too 239 
short on vaginal examination at time of procedure. R sults are presented by intention to treat however, as shown 240 
in Table 8, were similar when analysed as per protocol.  241 
DISCUSSION 242 
Principal Findings 243 
This is the first RCT comparing abdominal cerclage with vaginal cerclage.  Our findings show that 244 
transabdominal cerclage is superior to low vaginal cerclage in preventing early PTB for women with an 245 
unsuccessful previous vaginal cerclage pregnancy. Compared to LVC, there was no benefit of HVC. In addition, 246 
transabdominal cerclage was superior to low vaginal cerclage in preventing fetal loss (late miscarriage and 247 
stillbirth).  248 
 249 
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Clinical Implications 250 
Numbers needed to treat were modest to both prevent delivery before 32 weeks (<4) and to prevent fetal loss 251 
(<6), and therefore the uptake of this procedure is likely to be efficient and cost effective. Further work should 252 
establish the health economic impact of such procedures including the longer-term need for caesarean sctions 253 
and associated morbidity. 254 
 255 
Strengths and limitations 256 
Although our numbers were small, they were based on an anticipated large treatment effect and we achieved the 257 
assumed event rates in our protocol, suggesting our findings are unlikely to be subject to a type 1 error. We had 258 
crossovers during the trial, but fewer than 10% of participants (8/111), and following a post-hoc per rotocol 259 
analysis, the treatment effect was greater in favour of abdominal cerclage. 260 
Women with a history of failed cerclage are rare. It is challenging to randomise such women into a trial where 261 
there are strong prior beliefs as to the perceived risk or benefit of the intervention and, therefore, lack of 262 
equipoise. This explains the length of time needed to reach the recruitment target, in spite of the natio l 263 
multicentre trial design. We found clinicians reluctant to randomise, with many unwilling to perform, and others 264 
unwilling to withhold an abdominal cerclage, even in the context of a trial. In addition, women who have 265 
experienced multiple pregnancy losses have often extensively researched the treatment options and have a fix d 266 
idea of which intervention would be best for them, so are unwilling to be randomised. We were unable to collect 267 
accurate screening data due to the referral nature of the trial.  268 
The trial was underpowered to evaluate safety concerns and meaningful subgroup analysis was not possible. 269 
Absolute numbers of women with prior cervical surgery, history of UTI or BV do differ slightly between arms 270 
but as per the CONSORT guidance, it is not recommended to carry out comparisons of randomised differences 271 
as these are likely the result of chance rather than bi s, and can be misleading (9). Additionally we ere unable 272 
to analyse complications pre- and post-conception with the abdominal procedure due to their rarity (none) and 273 
small numbers. No clinicians used laparoscopic TAC procedures and we therefore could not evaluate possible 274 
differences between this and other techniques, suchas types of sutures. Other concerns related to abdminal 275 
cerclage include managing early miscarriage and infertility, were not apparent in this study. It is our experience, 276 
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however, that evacuation of the uterus for missed miscarriage, or termination of pregnancy for fetal abnormality 277 
can be safely performed up to 14 weeks, leaving the abdominal cerclage in place. 278 
Although the trial intended to evaluate rates of neonatal death, there were none. This suggests that women with 279 
a prior failed pregnancy before 28 weeks tend to have fetal losses at pre-viable gestations in the second 280 
trimester, if they recur.  The mechanism of pregnancy failure causing late miscarriage and early preterm birth 281 
(resulting in neonatal death) is likely to be the same, and as we excluded early miscarriage, we therefor  believe 282 
our fetal loss rates are a meaningful comparator across treatments, although not predefined.  283 
Comparison between TAC and HVC was not originally panned because we were investigating an improvement 284 
in preterm birth rates compared to standard practice, which at that time was LVC. Given the strong reduction in 285 
the rate of preterm birth in women with a TAC in situ, and the similarity between the groups with HVC and 286 
LVC, it was considered appropriate to also compare TAC with HVC. TAC was shown to strongly reduce 287 
preterm birth before 32 weeks compared to HVC as well as LVC. These results remained highly significant 288 
even after correcting for multiple testing using the Bonferroni correction (TAC v LVC, p=0.02, TAC v HVC, 289 
p=0.007). 290 
The mechanism of benefit is not clear, but our findings suggest that an abdominally placed cerclage may prevent 291 
the initiation of contractions. A previous study suggested that the higher the vaginal cervical cerclage is placed, 292 
the lower the risk of preterm birth (10) but this was in a more heterogeneous, lower risk population. In the very 293 
high-risk cohort of the present study, high vaginal cerclage was no better. The multiple and varied risk factors in 294 
the abdominal cerclage group suggests the treatment eff ct is unrelated to aetiology.  295 
 296 
Research Implications 297 
Severe complications were rare but those that did occur were in women with a vaginal procedure. Three of the 298 
four were related to cerclage failure, including cervical trauma at early birth, and sepsis. Multiple abdominal 299 
procedures associated with the abdominal cerclage may ultimately cause more longer-term morbidity and we 300 
were unable to evaluate this within this study. Future research should define longer-term morbidity associated 301 
with the procedure (e.g. pelvic pain, repeat surgery) alongside a health economic evaluation of the procedure 302 
and its outcomes over a woman’s reproductive life, but should include the reduced morbidity associated with 303 





While further research is needed to confirm the value of TAC in other high-risk groups, our findings suggest it 308 
is likely to be beneficial to women with previous failed vaginal cerclage. Implications for practice include the 309 
need to increase the availability of transabdominal cerclage for suitable women, and the training of obstetricians 310 
in this uncommon practice. The procedure is not technically difficult and most gynaecologists who undertake 311 
any form of pelvic surgery should be equipped with the fundamental skills.  312 
 313 
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FIGURES AND TABLES 336 
Figure 1: Participant flow chart with treatment all ocation and exclusions 337 
 338 
 339 






















Delivery before 24 



































 Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Age at time of consent (years)  319 (51) 321 (53) 318 (51) 323 (54) 
BMI (kg/m2) 299 (69) 301 (70) 299 (69) 301 (70) 
Social class/occupation  n (%) n (%) n (%) n (%) 
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Table 2: Maternal baseline demographic characteristics 345 
 346 
Table 3: Cohort risk factors for spontaneous preterm birth by treatment allocation 347 










Cervical surgery 2 (5%) 6 (15%) 9 (27%) 17 (15%) 
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2 or more second trimester 
losses (%, n) 
97% (38/39) 95% (37/39) 91% (30/33) 95% 
(105/111) 
Congenital Uterine Anomaly  3 (8%) 4 (10%) 3 (9%) 10 (9%) 
    Managerial/professional 12 (31%) 17 (44%) 13 (39%) 42 (38%) 
    Intermediate 20 (51%) 18 (46%) 14 (42%) 52 (47%) 
    Routine/unemployed 7 (18%) 4 (10%) 6 (18%) 17 (5%) 
Ethnicity     
    White 11 (28%) 10 (26%) 12 (36%) 33 (30%) 
    Black  21 (54%) 23 (59%) 18 (55%) 62 (56%) 
    Asian  4 (10%) 5 (13%) 3 (9%) 12 (11%) 
    Other 3 (8%) 1 (3%) 0 (0%) 4 (4%) 
 18
Antiphospholipid syndrome 
(anticardiolipin or lupus 
anticoagulant) 
1 (3%) 2 (5%) 0 (0%) 3 (3%) 
Smoked during pregnancy 3(8%) 1(3%) 4 (12%) 8 (7%) 
     
Past or present history of:     
Recurrent UTIs (>2) in 
pregnancy  
3(8%) 4 (10%) 7 (21%) 14 (13%) 
Group B Streptococcus 11 (28%) 10 (26%) 3(9%) 24 (22%) 
Bacterial Vaginosis 3(8%) 4 (10%) 4 (12%) 11 (10%) 
Recreational drug use  1(3%) 0 (0%) 2 (6%) 3 (3%) 
Domestic Violence 0(0%) 0 (0%) 0 (0%) 0 (0%) 
 348 
 349 
Table 4: Pregnancy outcome by randomised allocation 350 






Preterm (<32 weeks)* 3 (8%) 15 (38%)  11 (33%) 
Preterm (<34 weeks)  4 (10%) 18 (46%) 13 (39%) 
Preterm (<37 weeks) 11 (28%)   21 (54%)  17 (52%) 
*primary outcome    
Live birth      38 (92%)  31 (79%) 26 (79%) 
Late Miscarriage 1 (3%) 7 (18%) 7 (21%) 
Stillbirth 0 (0%) 1 (3%) 0 (0%) 
 19
All fetal losses 1 (3%) 8 (21%) 7 (21%) 
*primary outcome 351 
 352 
Table 5: Details of patient crossovers from randomised allocation to treatment received 353 
ID Randomisation Final 
procedure 
Gestation - details Outcome 
24 LVC TAC At 10+0 – patient preference 39+1 
56 LVC TAC Preconception - patient choice 36+0 
66 LVC HVC At 14+0 – patient preference 37+5 
79 HVC TAC At 12+5 – patient preference 38+6 
87 TAC LVC At 10+6 – patient preference 38+0 
88 LVC TAC 10+2 - No vaginal cervix on 
digital examination 
37+6 
111 TAC HVC 13+3 - patient request 38+5 
133 LVC HVC 13+0 – transfer of care 38+2 
 354 
Table 6: Details of surgical and anaesthetic techniques 355 
Procedure techniques Transabdominal 
cerclage 
(N=39) 
High vaginal cerclage 
 
(n=39) 































*all other sutures were performed using monofilament suture **inserted simultaneously at the time of procedure 356 
 357 
Table 7: Operative details per randomisation arm 358 
PTB <32/40 TAC (n=39) HVC (n=39) LVC (n=33) 
Consultant grade surgeon 100% 100% 100% 
Number of surgeons 
 
7 4 7 
Blood loss  
(median, IQR) 
100 (50 to 150) 35 (20 to 60) 5 (5 to 20) 
Operative time* (mins) 
(median, IQR) 
42 (30 to 50) 13.5 (10 to 15) 25 (20 to 32) 
















Concurrent progesterone 17% (6/36) 28% (10/36) 48% (14/29) 
Rescue cerclage 0% (0/39) 10% (4/39) 6% (2/33) 
*start of operation to completion 359 
 360 
Table 8: Primary outcomes by intention to treat and as per protocol analysis  361 
 Preterm birth < 32 weeks Fetal loss 
 Intention to treat 
analysis 
As per protocol 
analysis 
Intention to treat 
analysis 
As per protocol 
analysis 

































































TAC versus LVC 
RR 023 
(007 to 076) 
p=00078 
021 
(065 to 070) 
p=00059 
012 
(0016 to 093) 
p=002 
011 
(0014 to 086) 
p=0018 
TAC versus HVC 
RR 02 
(0063 to 064) 
p=00024 
019 
(0058 to 059) 
p=0001 
013 
(0016 to 095) 
p=0029 
012 
(0015 to 088) 
p=0012 
HVC versus LVC 
RR 115 
(062 to 216) 
p=081 
115 
(062 to 213) 
p=080 
097 
(039 to 238) 
p=100 
096 
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Table 2: Maternal baseline demographic characteristics 
 








 Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
Age at time of consent (years)  319 (51) 321 (53) 318 (51) 323 (54) 
BMI (kg/m2) 299 (69) 301 (70) 299 (69) 301 (70) 
Social class/occupation  n (%) n (%) n (%) n (%) 
    Managerial/professional 12 (31%) 17 (44%) 13 (39%) 42 (38%) 
    Intermediate 20 (51%) 18 (46%) 14 (42%) 52 (47%) 
    Routine/unemployed 7 (18%) 4 (10%) 6 (18%) 17 (15%) 
Ethnicity     
    White 11 (28%) 10 (26%) 12 (36%) 33 (30%) 
    Black  21 (54%) 23 (59%) 18 (55%) 62 (56%) 
    Asian  4 (10%) 5 (13%) 3 (9%) 12 (11%) 
    Other 3 (8%) 1 (3%) 0 (0%) 4 (4%) 
Table 3: Cohort risk factors for spontaneous preterm birth by treatment allocation 









Cervical surgery 2   (5%) 6 (15%) 9 (27%) 17 (15%) 

















1 to 5 
History of early delivery (late 















Uterine anomaly  3   (8%) 4 (10%) 3   (9%) 10   (9%) 
Antiphospholipid syndrome 
(anticardiolipin or lupus 
anticoagulant) 
1   (3%) 2   (5%) 0   (0%) 3   (3%) 
Smoked during pregnancy 3   (8%) 1   (3%) 4 (12%) 8   (7%) 
     
Past or present history of:     
Recurrent UTIs (>2) in 
pregnancy  
3   (8%) 4 (10%) 7 (21%) 14 (13%) 
Group B Streptococcus 11 (28%) 10 (26%) 3   (9%) 24 (22%) 
Bacterial Vaginosis 3   (8%) 4 (10%) 4 (12%) 11 (10%) 
Recreational drug use  1   (3%) 0   (0%) 2   (6%) 3   (3%) 
Domestic Violence 0   (0%) 0   (0%) 0   (0%) 0   (0%) 
 
Table 4: Pregnancy outcome by randomised allocation 






Preterm (<32 weeks)* 3 (8%) 15 (38%)  11 (33%) 
Preterm (<34 weeks)  4 (10%) 18 (46%) 13 (39%) 
Preterm (<37 weeks) 11 (28%)   21 (54%)  17 (52%) 
*primary outcome    
Live birth      38 (92%)  31 (79%) 26 (79%) 
Late Miscarriage 1 (3%) 7 (18%) 7 (21%) 
Stillbirth 0 (0%) 1 (3%) 0 (0%) 




Table 5: Details of patient crossovers from randomised allocation to treatment received 
ID Randomisation Final 
procedure 
Gestation - details Outcome 
24 LVC TAC At 10+0 – patient preference 39+1 
56 LVC TAC Preconception - patient choice 36+0 
66 LVC HVC At 14+0 – patient preference 37+5 
79 HVC TAC At 12+5 – patient preference 38+6 
87 TAC LVC At 10+6 – patient preference 38+0 
88 LVC TAC 10+2 - No vaginal cervix on 
digital examination 
37+6 
111 TAC HVC 13+3 - patient request 38+5 
133 LVC HVC 13+0 – transfer of care 38+2 
 
Table 6: Details of surgical and anaesthetic techniques 
*all other sutures were performed using monofilament suture **inserted simultaneously at the time of procedure 
 
Procedure techniques Transabdominal 
cerclage 
(N=39) 
High vaginal cerclage 
 
(n=39) 






























































































Table 7: Operative details per randomisation arm 
PTB <32/40 TAC (n=39) HVC (n=39) LVC (n=33) 
Consultant grade surgeon 100% 100% 100% 
Number of surgeons 
 
7 4 7 
Blood loss  
(median, IQR) 
100 (50 to 150) 35 (20 to 60) 5 (5 to 20) 
Operative time* (mins) 
(median, IQR) 
42 (30 to 50) 13.5 (10 to 15) 25 (20 to 32) 
















Concurrent progesterone 17% (6/36) 28% (10/36) 48% (14/29) 
Rescue cerclage 0% (0/39) 10% (4/39) 6% (2/33) 
*start of operation to completion 
 
Table 8: Primary outcomes by intention to treat and as per protocol analysis  
 Preterm birth < 32 weeks Fetal loss 
 Intention to treat 
analysis 
As per protocol 
analysis 
Intention to treat 
analysis 
As per protocol 
analysis 
TAC versus LVC 
RR 023 
(007 to 076) 
p=00078 
021 
(065 to 070) 
p=00059 
012 
(0016 to 093) 
p=002 
011 
(0014 to 086) 
p=0018 
TAC versus HVC 
RR 02 
(0063 to 064) 
p=00024 
019 
(0058 to 059) 
p=0001 
013 
(0016 to 095) 
p=0029 
012 
(0015 to 088) 
p=0012 
HVC versus LVC 
RR 115 
(062 to 216) 
p=081 
115 
(062 to 213) 
p=080 
097 
(039 to 238) 
p=100 
096 
(039 to 236) 
p=100 
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P
er
ce
nt
ag
e 
(%
)
Pregnancy Outcome
LVC n=33
HVC n=39
TAC n=39
